Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tissue-engineered valves give diseased hearts new life

12.11.2003


American Heart Association meeting report



Heart valves engineered from patients’ own tissue may offer a new treatment for valvular heart disease, researchers reported today at the American Heart Association’s Scientific Sessions 2003.

"Using this tissue-engineered valve overcomes many of the problems with mechanical or donor valves because it is a living structure from the patient’s own tissue, and so it does not cause an immunological reaction," said Pascal M. Dohmen, M.D., head of tissue engineering research and staff surgeon of the department of cardiovascular surgery at Charité Hospital in Berlin, Germany.


Dohmen and colleagues presented data on the first 23 patients to receive tissue-engineered pulmonary valves in the heart.

The patients, whose average age was 44, had aortic valve disease. The aortic valve connects the heart’s left ventricle with the aorta, the main artery that distributes blood throughout the body. A diseased valve may either open or close improperly, and pressure can build in the ventricle, injuring the heart.

Doctors can treat the condition with drugs or by surgically replacing the patient’s aortic valve with a donor valve, a mechanical valve or the patient’s pulmonary valve. The pulmonary valve is between the right ventricle and the pulmonary artery. In a surgical "swap" called the Ross procedure, the abnormal aortic valve is replaced with the pulmonary valve, and the pulmonary valve is replaced with a donor valve.

Dohmen and colleagues engineered a new pulmonary valve from the patients’ own cells. They implanted the patients’ healthy pulmonary valve into the aortic position. Then they implanted the tissue-engineered valve in the right ventricular outflow tract, where the pulmonary valve originally was.

With up to three years of follow-up, the engineered valve’s performance was "excellent," Dohmen reported. Echocardiography showed that the valves were functioning normally; the valve leaflets or flaps appeared smooth and pliable and showed no signs of calcification.

The patients were discharged from the hospital earlier, and were in better condition than other patients. They had no post-operative fever, which is often found in patients receiving donor heart valves, Dohmen said. Furthermore, the recovery time was shorter.

To engineer the new valve leaflets, the investigators extracted a small portion of vein from the patients’ leg or arm. Then they grew endothelial cells from the vein on a donor valve scaffold in the laboratory. The scaffold had been stripped of cells, leaving only an elastin and collagen matrix for binding the patients’ cells.

"In animal studies, we have seen that this matrix or scaffold will be absorbed by the body," Dohmen said. "In the mean time, the patient’s cells will form a new scaffold. After about a year, the matrix is of the patients’ own material.

"The problem until now was to reconstruct the right ventricular outflow tract," he said. "You cannot do this with regular animal (pig) or human donor valves because they will calcify early or degenerate soon after implantation, especially in patients under the age of 60."

Dohmen limits the use of the tissue-engineered valves to adults up to 60 years of age, but plans to explore the growth potential of the valves, with the hope of using them in children with congenital heart disease.

The heart valve scaffold technique is still considered experimental, he said.


Co-authors are Simon Dushe, Alexander Lembcke, Dietmar Kivelitz, Holger Hotz and Wolfgang F. Konertz.

Carole Bullock | EurekAlert!
Further information:
http://www.americanheart.org/

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

New insights into the ancestors of all complex life

29.05.2017 | Earth Sciences

New photocatalyst speeds up the conversion of carbon dioxide into chemical resources

29.05.2017 | Life Sciences

NASA's SDO sees partial eclipse in space

29.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>